BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. J Crohns Colitis 2018;12:1014-20. [PMID: 29846530 DOI: 10.1093/ecco-jcc/jjy070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Mariaule V, Kriaa A, Soussou S, Rhimi S, Boudaya H, Hernandez J, Maguin E, Lesner A, Rhimi M. Digestive Inflammation: Role of Proteolytic Dysregulation. Int J Mol Sci 2021;22:2817. [PMID: 33802197 DOI: 10.3390/ijms22062817] [Reference Citation Analysis]
2 de Bruyn M, Ferrante M. Failure of MMP-9 Antagonists in IBD: Demonstrating the Importance of Molecular Biology and Well-Controlled Early Phase Studies. J Crohns Colitis 2018;12:1011-3. [PMID: 30010739 DOI: 10.1093/ecco-jcc/jjy102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Prado AF, Batista RIM, Tanus-Santos JE, Gerlach RF. Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations. Biomolecules 2021;11:585. [PMID: 33923477 DOI: 10.3390/biom11040585] [Reference Citation Analysis]
4 Nandi SS, Katsurada K, Sharma NM, Anderson DR, Mahata SK, Patel KP. MMP9 inhibition increases autophagic flux in chronic heart failure. Am J Physiol Heart Circ Physiol 2020;319:H1414-37. [PMID: 33064567 DOI: 10.1152/ajpheart.00032.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yablecovitch D, Kopylov U, Lahat A, Amitai MM, Klang E, Ben-Ami Shor D, Neuman S, Levhar N, Fudim E, Avidan B, Laish I, Selinger L, Zingboim-Orbach N, Picard O, Yavzori M, Eliakim R, Ben-Horin S. Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a post hoc analysis. Therap Adv Gastroenterol 2019;12:1756284819881590. [PMID: 31636712 DOI: 10.1177/1756284819881590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Oncel S, Basson MD. Gut homeostasis, injury, and healing: New therapeutic targets. World J Gastroenterol 2022; 28(17): 1725-1750 [DOI: 10.3748/wjg.v28.i17.1725] [Reference Citation Analysis]
7 Fogg KC, Olson WR, Miller JN, Khan A, Renner C, Hale I, Weisman PS, Kreeger PK. Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway. Cancer Lett 2019;458:92-101. [PMID: 31129149 DOI: 10.1016/j.canlet.2019.05.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
8 Marônek M, Marafini I, Gardlík R, Link R, Troncone E, Monteleone G. Metalloproteinases in Inflammatory Bowel Diseases. J Inflamm Res 2021;14:1029-41. [PMID: 33790618 DOI: 10.2147/JIR.S288280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. Genetic drug target validation using Mendelian randomisation. Nat Commun 2020;11:3255. [PMID: 32591531 DOI: 10.1038/s41467-020-16969-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
10 Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. Cells. 2020;9. [PMID: 32466129 DOI: 10.3390/cells9051313] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
11 Yu B, Zhao L, Jin S, He H, Zhang J, Wang X. Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease. Front Immunol 2022;13:828219. [DOI: 10.3389/fimmu.2022.828219] [Reference Citation Analysis]